The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

British Journal of Dermatology

Volumn 173, Issue 3, 2015, Pages 855-857

  Menting, S P ^a   Van Den Reek, J M P A ^b   Baerveldt, E M ^c   De Jong, E M G J ^b   Prens, E P ^c   Lecluse, L L A ^a   Wolbink, G J ^d   Van Der Kleij, D ^d,e   Spuls, Ph I ^a   Rispens, T ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

^e Sanquin Diagnostiek   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; USTEKINUMAB; ANTIBODY; ANTIGEN; DERMATOLOGICAL AGENT;

ANTIGEN BINDING; CLINICAL PRACTICE; CORRELATIONAL STUDY; DRUG EFFICACY; ELECTIVE SURGERY; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; BINDING SITE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ANTIBODIES; ANTIGENS; BINDING SITES; DERMATOLOGIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; USTEKINUMAB;

EID: 84942366022     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13834     Document Type: Letter

References (10)

1. Kimball AB, Papp KA, Wasfi Y, et al., Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
2. Menting SP, van Lümig PP, de Vries AC, et al., Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol 2014; 150: 130-6.
3. Pouw MF, Krieckaert CL, Nurmohamed MT, et al., Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015; 74: 513-18.
4. Hart MH, de Vrieze H, Wouters D, et al., Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372: 196-203.
5. Hsu L, Snodgrass BT, Armstrong AW,. Anti-drug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170: 261-73.
6. van Schouwenburg PA, Bartelds GM, Hart MH, et al., A novel method for the detection of antibodies to adalimumab in the presence of drug reveals 'hidden' immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362: 82-8.
7. Rispens T, Leeuwen A, Vennegoor A, et al., Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem 2011; 411: 271-6.
8. Wolbink GJ, Vis M, Lems W, et al., Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-15.
9. Rispens T, de Vrieze H, de Groot E, et al., Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods 2012; 375: 93-9.
10. Gottlieb AB, Cooper KD, McCormick TS, et al., A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007; 23: 1081-92.